35,000
people die of chronic or cirrhotic liver diseases each year in US
13,705
patients were on the waiting list for a liver transplantation in the US in 2016
7,841
liver transplants were reported in the US in 2016

Promethera® Biosciences aims to bring patients life-saving treatments to reduce the need for liver transplantation.

Our passion translates into a commitment to holistically change patients’ lives by not only developing pioneering liver therapies, but also providing high quality education about liver disease and how to prevent it through healthy lifestyle choices.

We are developing cutting-edge cell- and antibody-based therapies for the treatment of liver diseases.

HepaStem is our most advanced cell-based therapy which has the potential to deliver novel treatment options for chronic and acute liver diseases including Acute-on-Chronic Liver Failure (ACLF), fibrosis and Non-Alcoholic SteatoHepatitis (NASH).

A unique set of technological assets, exclusive IP & know-how.

A broad intellectual property portfolio, which includes a proprietary antibody therapy, human organ and cell sourcing and manufacturing capabilities, positions the Promethera® Group as a global leader in regenerative medicine and cell therapy for liver diseases.

Restoring Liver Health

Twitter feed

We are ready for the next Jobdays organized by @essenscia. Come and meet @Promethera team members next Tuesday 10th March, see you there! #Jobs #careerchange #DreamTeam #craftyourcareer #talentscouting

Tomorrow, 5th March, our PI Prof F. Nevens from @UZLeuven will be presenting the safety and preliminary efficacy data on #HepaStem in patients with #ACLF or #AD at risk of developing ACLF at the Belgian Week of Gastroenterologie.
#Promethera #bwge #liverdisease

📣 WE ARE HIRING! We have several new job openings 👉 Check out our website for more details https://buff.ly/2IcjSfU Keen to meet Promethera team members live? Don't hesitate to pay us a visit at the @essenscia Job Days on 10th March at the Cercle du Lac, LLN.